Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 574 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.
Follow-Up Questions
Quel est le ratio P/E de Gyre Therapeutics Inc (GYRE) ?
Le ratio P/E de Gyre Therapeutics Inc est de 62.38
Quelle est la performance du prix de l'action GYRE ?
Le prix actuel de GYRE est de $8.3, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Gyre Therapeutics Inc ?
Gyre Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Gyre Therapeutics Inc ?
La capitalisation boursière actuelle de Gyre Therapeutics Inc est de $753.8M
Est-ce que Gyre Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Gyre Therapeutics Inc, y compris 2 achat fort, 5 achat, 1 maintien, 0 vente et 2 vente forte
